Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 271Lymphoid 229Other hematologic neoplasm 201Myeloid 106CNS 59Sarcoma 46Classical hematology 38Dermatologic 36Gastrointestinal 18Other solid neoplasm 16Breast 14Genitourinary 13Gynecologic 12Other neoplasm 5Other 2Endocrine 2Thoracic 1

Conditions

Mucositis 2Multiple Myeloma 1Leukemia 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Exercise 27Metformin 24Methods 14Radiotherapy 13Early Intervention, Educational 13Educational Status 12Counseling 12Surveys and Questionnaires 10Standard of Care 10Nutrition Assessment 9Resistance Training 8Diet Therapy 8Cisplatin 8naloxegol 7Tirzepatide 7Diet 7alvimopan 6Psychiatric Rehabilitation 6Fibroblast Growth Factor 7 6Caloric Restriction 6Radiation 5Low-Level Light Therapy 5Liraglutide 5Injections 5Exenatide 5Dexamethasone 5Cryotherapy 5semaglutide 4angiotensin I (1-7) 4Vitamin D 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Melphalan × Other × Clear all
NCT01085617 2025-03-30

UKALL14

University College, London

Completed
OtherOther hematologic neoplasm

Leukemia, Mucositis

NCT00482846 2014-04-15

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
38 enrolled
OtherPlasma cell

Multiple Myeloma, Mucositis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡